Overview

Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Irinotecan